サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1555486

ハンチントン病治療市場：診断タイプ別、治療タイプ別、薬剤タイプ別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Huntington's Disease Treatment Market, By Diagnosis Type, By Treatment Type, By Drug Type, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 284 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
ハンチントン病治療市場：診断タイプ別、治療タイプ別、薬剤タイプ別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年08月04日
発行: AnalystView Market Insights
ページ情報: 英文 284 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

ハンチントン病治療市場規模は2023年に4億5,090万米ドルと評価され、2024年から2032年にかけて24.10%のCAGRで拡大

ハンチントン病治療市場-市場力学

ハンチントン病患者の急増と、同疾患に対処するための最先端薬剤への要求の高まりが市場成長を促進すると予測される

ハンチントン病に関する知識の増加と診断ツールの進歩により、早期発見と早期介入が可能になり、治療選択の必要性が高まっています。この退行性脳疾患は、10万人あたり約3～7人が罹患し、主に欧州人の祖先を持つ人に発症します。製薬会社や研究機関は、新たな治療法の発見や既存の治療法の改善のための研究開発に多大な資源を投入しており、市場の成長を後押ししています。さらに、薬剤研究の進歩は市場拡大の可能性をさらに広げます。しかし、新興国市場における認知度の低さは、市場の進展を阻害する可能性があります。

ハンチントン病治療市場-主要インサイト

弊社のリサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約24.10%のCAGRで毎年成長すると推定されます。

診断タイプ別では、画像診断が2023年に最大の市場シェアを示すと予測されています。

治療タイプ別では、対症療法が2023年の主要タイプでした。

薬剤タイプ別では、2023年にテトラベナジンが主要タイプに

エンドユーザー別では、2023年には病院薬局が主要タイプでした。

地域別では、北米が2023年に収益でリードしました。

ハンチントン病治療市場-セグメンテーション分析：

世界のハンチントン病治療市場は、診断タイプ、治療タイプ、薬剤タイプ、エンドユーザー、地域に基づいてセグメント化されます。

市場は診断タイプによって2つのグループに分類される：画像診断、遺伝子検査、その他です。画像診断が最大のシェアを占めています。ハンチントン病治療市場の画像診断分野は、診断、モニタリング、治療効果の評価の精度を高める技術の進歩により進歩しています。

市場は治療タイプによって2つに区分される：すなわち、対症療法、疾患修飾療法、その他です。対症療法が市場の大半を占めています。対症療法市場には、運動機能障害、精神症状、認知機能低下など、HDの様々な症状の管理を目的とした様々な方法・治療が含まれます。

市場は薬剤の種類によって2つのグループに区分される：テトラベナジン、ドイテトラベナジン、その他の薬剤です。テトラベナジンは市場で最大のシェアを占めています。テトラベナジンは主に、ハンチントン病の代表的な障害症状である舞踏病の治療薬として処方されます。舞踏病は不随意で突発的な動きを特徴とし、日常生活や動作に大きな影響を与えます。

市場はエンドユーザーによって、病院薬局、小売薬局、オンライン薬局の3つに区分されます。病院薬局は市場をリードするセクターです。病院薬局は、投薬管理、調剤、患者ケア、治療サポートにおいて重要な役割を果たしています。

ハンチントン病治療市場-地理的洞察

ハンチントン病治療市場は、北米、ラテンアメリカ、欧州、アジア太平洋、中東アフリカにまたがっています。これらの地域は、事業活動に貢献している国によってさらに区分されます。北米は、疾患修飾療法に対する需要の高まりが市場を牽引しています。この地域には、ハンチントン病の疾患修飾療法の研究開発に積極的に関与している著名な製薬企業やバイオテクノロジー企業が複数存在します。国立保健統計センターによると、2019年、成人の19.2％が過去12カ月間に何らかのメンタルヘルス治療を受けており、15.8％が処方薬を使用し、9.5％がメンタルヘルス専門家からカウンセリングや治療を受けていました。欧州は、認知度の向上と早期診断に起因する市場成長の第2位の地域です。

ハンチントン病治療市場-競合情勢：

メーカーは、疾患修飾治療や革新的な対症療法の開発に多額の研究開発投資を行うことに注力しています。神経保護剤や高度な遺伝子編集技術など、さまざまなアプローチが企業や研究機関によって模索されています。新薬や治療戦略を検証するための臨床試験は多くの企業によって実施されており、次世代のHD治療法の開発競争につながっています。カウンセリングや教育を含む包括的な患者支援プログラムを提供する企業は、患者のアドヒアランスと満足度を向上させることで競争優位に立てる可能性があります。

目次

第1章 ハンチントン病治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 ハンチントン病治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 ハンチントン病治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 ハンチントン病治療市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 ハンチントン病治療市場情勢

  • ハンチントン病治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 ハンチントン病治療市場- 診断タイプ別

  • 概要
    • 診断タイプ別セグメントシェア分析
    • 診断画像
    • 遺伝子検査
    • その他

第8章 ハンチントン病治療市場- 治療タイプ別

  • 概要
    • 治療タイプ別セグメントシェア分析
    • 対症療法
    • 疾患修飾療法
    • その他

第9章 ハンチントン病治療市場- 薬剤タイプ別

  • 概要
    • 薬剤タイプ別セグメントシェア分析
    • テトラベナジン
    • デュテトラベナジン
    • その他の薬物

第10章 ハンチントン病治療市場- エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局

第11章 ハンチントン病治療市場- 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- ハンチントン病治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Pfizer Inc.
    • Alnylam Pharmaceuticals Inc.
    • Ceregene Inc.
    • Prana Biotechnology Limited
    • Teva Pharmaceutical Industries Ltd
    • Ionis Pharmaceuticals
    • Neurocrine Biosciences Inc.
    • Prilenia Therapeutics
    • Azevan Pharmaceuticals
    • Lundbeck
    • PTC Therapeutics
    • UniQure
    • Others

第13章 アナリストの全方位展望

目次
Product Code: ANV3593

REPORT HIGHLIGHT

Huntington's Disease Treatment Market size was valued at USD 450.90 million in 2023, expanding at a CAGR of 24.10% from 2024 to 2032.

Huntington's disease is a rare genetic disorder that currently has no cure and causes the deterioration of brain cells. Early signs often include problems with coordination and occasional memory lapses. This disease has a significant impact on a person's motor skills, cognitive functions, and overall mental health. The rarity of Huntington's disease is notable, as it is usually passed down through a mutated gene from one of the parents. The disorder mainly results in a range of movement difficulties, as well as mental health challenges and issues with cognitive processes like planning and reasoning. According to the Genetic and Rare Diseases Information Center (GARD), there are fewer than 5,000 individuals in the United States living with Huntington's disease.

Huntington's Disease Treatment Market- Market Dynamics

The surge in Huntington's disease cases and the escalating requirement for cutting-edge drugs to address the disease are projected to fuel market growth

Increased knowledge about Huntington's disease, along with advancements in diagnostic tools, is enabling early identification and intervention, leading to a rise in the need for treatment choices. This degenerative brain condition affects around 3 to 7 people per 100,000, mainly in individuals of European ancestry. Pharmaceutical companies and research institutions are dedicating significant resources to research and development to discover new treatment options and improve existing therapies, thereby fueling the growth of the market. Furthermore, advancements in drug research offer additional possibilities for market expansion. However, a lack of awareness in developing areas could impede the progress of the market.

Huntington's Disease Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 24.10% over the forecast period (2024-2032)

Based on Diagnosis Type segmentation, Diagnostic Imaging was predicted to show maximum market share in the year 2023

Based on Treatment Type segmentation, Symptomatic Therapy was the leading type in 2023

Based on Drug Type segmentation, Tetrabenazine was the leading type in 2023

Based on End-User segmentation, Hospital Pharmacies was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Huntington's Disease Treatment Market- Segmentation Analysis:

The Global Huntington's Disease Treatment Market is segmented based on Diagnosis Type, Treatment Type, Drug Type, End-User, and Region.

The market is categorized into two groups according to Diagnosis Type: Diagnostic Imaging, Genetic Testing, and Others. Diagnostic Imaging holds the largest share of the market. The diagnostic imaging sector of Huntington's disease Treatment Market is progressing due to technological advancements that enhance the precision of diagnosis, monitoring, and assessment of treatment effectiveness.

The market is segmented into two categories according to Treatment Type: Symptomatic Therapy, Disease-Modifying Therapy, and Others. Symptomatic Therapy holds the majority share in the market. The market for symptomatic therapy treatment encompasses a range of methods and treatments aimed at managing the various symptoms of HD, such as motor dysfunction, psychiatric symptoms, and cognitive decline.

The market is segmented into two groups according to Drug Type: Tetrabenazine, Deutetrabenazine, and Other Drugs. Tetrabenazine holds the largest share of the market. Tetrabenazine is mainly prescribed for the treatment of chorea, a prevalent and disabling symptom of Huntington's disease. Chorea is characterized by involuntary, abrupt movements that can greatly affect everyday activities and movement.

The market is segmented into three categories according to End-User: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies are the leading sector in the market. They play a vital role in medication management, dispensing, patient care, and treatment support.

Huntington's Disease Treatment Market- Geographical Insights

Geographically, this market spans across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further segmented by countries contributing to business activities. North America leads the market, driven by the increasing demand for disease-modifying therapies. This region is home to several prominent pharmaceutical and biotechnology companies actively involved in the research and development of disease-modifying therapies for Huntington's disease. According to the National Center for Health Statistics, in 2019, 19.2% of adults had received some form of mental health treatment in the past 12 months, with 15.8% using prescription medication and 9.5% receiving counseling or therapy from a mental health professional. Europe is the second-largest region for market growth, attributed to rising awareness and early diagnosis.

Huntington's Disease Treatment Market- Competitive Landscape:

Manufacturers are concentrating on making significant R&D investments in the development of disease-modifying treatments and innovative symptomatic therapies. Various approaches, such as neuroprotective agents and advanced gene-editing techniques, are being explored by companies and research institutions. Clinical trials to test new drugs and treatment strategies are being conducted by many companies, leading to competition in the advancement of the next generation of HD therapies. Companies that provide comprehensive patient support programs, including counseling and education, may gain a competitive advantage by improving patient adherence and satisfaction.

Recent Developments:

A recent interim update on the phase 1/2 trials for uniQure's experimental gene therapy AMT-130 revealed that administering high doses of the treatment led to a notable deceleration of disease advancement and reduction of neurofilament light (NfL) levels in individuals with Huntington's disease (HD).

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • Alnylam Pharmaceuticals Inc.
  • Ceregene Inc.
  • Prana Biotechnology Limited
  • Teva Pharmaceutical Industries Ltd
  • Ionis Pharmaceuticals
  • Neurocrine Biosciences Inc.
  • Prilenia Therapeutics
  • Azevan Pharmaceuticals
  • Lundbeck
  • PTC Therapeutics
  • UniQure
  • Others

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DIAGNOSIS TYPE- MARKET ANALYSIS, 2019 - 2032

  • Diagnostic Imaging
  • Genetic Testing
  • Others

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Symptomatic Therapy
  • Disease-Modifying Therapy
  • Others

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Tetrabenazine
  • Deutetrabenazine
  • Other Drugs

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Huntington's Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Huntington's Disease Treatment Market Snippet by Diagnosis Type
    • 2.1.2. Huntington's Disease Treatment Market Snippet by Treatment Type
    • 2.1.3. Huntington's Disease Treatment Market Snippet by Drug Type
    • 2.1.4. Huntington's Disease Treatment Market Snippet by End-User
    • 2.1.5. Huntington's Disease Treatment Market Snippet by Country
    • 2.1.6. Huntington's Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Huntington's Disease Treatment Key Market Trends

  • 3.1. Huntington's Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Huntington's Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Huntington's Disease Treatment Market Opportunities
  • 3.4. Huntington's Disease Treatment Market Future Trends

4. Huntington's Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Huntington's Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Huntington's Disease Treatment Market Landscape

  • 6.1. Huntington's Disease Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Huntington's Disease Treatment Market - By Diagnosis Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Diagnosis Type, 2023 & 2032 (%)
    • 7.1.2. Diagnostic Imaging
    • 7.1.3. Genetic Testing
    • 7.1.4. Others

8. Huntington's Disease Treatment Market - By Treatment Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
    • 8.1.2. Symptomatic Therapy
    • 8.1.3. Disease-Modifying Therapy
    • 8.1.4. Others

9. Huntington's Disease Treatment Market - By Drug Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 9.1.2. Tetrabenazine
    • 9.1.3. Deutetrabenazine
    • 9.1.4. Other Drugs

10. Huntington's Disease Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Huntington's Disease Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Huntington's Disease Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Huntington's Disease Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Huntington's Disease Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Huntington's Disease Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Huntington's Disease Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Huntington's Disease Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Pfizer Inc.
    • 12.2.2. Alnylam Pharmaceuticals Inc.
    • 12.2.3. Ceregene Inc.
    • 12.2.4. Prana Biotechnology Limited
    • 12.2.5. Teva Pharmaceutical Industries Ltd
    • 12.2.6. Ionis Pharmaceuticals
    • 12.2.7. Neurocrine Biosciences Inc.
    • 12.2.8. Prilenia Therapeutics
    • 12.2.9. Azevan Pharmaceuticals
    • 12.2.10. Lundbeck
    • 12.2.11. PTC Therapeutics
    • 12.2.12. UniQure
    • 12.2.13. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us